Safe Orthopaedics announces the forthcoming arrival of its new Chief Financial Officer and the strengthening of its sales team

Eragny-sur-Oise (France), September 14, 2017, 6:00p.m. – SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, is today announcing that its new Chief Financial Officer will join the Company by the end of November 2017 as a replacement for Thierry Lambert, as well as the strengthening of its sales and marketing team with the recruitment of five new employees

The name of the new Chief Financial Officer, who is currently working for another listed company and boasts tremendous experience of growth companies, will be announced shortly once s/he takes up the position. In the meantime, the CFO's duties will be handled jointly by Pierre Dumouchel, Chief Executive Officer, and the Head of Financial Control.

"On behalf of the entire team, I would like to place on record our deepest gratitude to Thierry Lambert for the major role he has played over the past two years, which helped us to rebuild on firm foundations", said Pierre Dumouchel, Chief Executive Officer and co-Founder of Safe Orthopaedics. "The arrival of our new Chief Financial Officer will mark the beginning of a new phase in Safe Orthopaedics' development as we seek to keep our expansion going. Recently we further strengthened our sales and marketing teams by hiring three new sales representatives—two in Germany and one in France—and two senior marketing specialists."

Next report: First-half 2017 results on Thursday, September 28 (after market close)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that aims to make spinal surgeries safer by using sterile implants and associated single-use instruments. Through this approach, these products eliminate all risk of contamination, reduce infection risks and facilitate a minimally-invasive approach for trauma and degenerative pathologies—benefiting patients. Protected by 17 patent families, the SteriSpineTM kits are CEmarked and FDA approved. The company is based at Eragny-sur-Oise (Val d'Oise department), and has 30 employees.

For more information, visit: www.SafeOrtho.com

Contacts

Safe Orthopaedics Pierre Dumouchel CEO

Tél.: +33 (0)1 34 21 50 00

investors@safeorthopaedics.com

NewCap
Julien Perez / Valentine Brouchot
Investor Relations

Nicolas Merigeau *Media Relations*

Tél.: +33 (0)1 44 71 94 94 SafeOrtho@newcap.eu

